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1. Founding Principles and Aims
The Faculty of Pharmaceutical Medicine (the Faculty) 
is a standard-setting body for the medical specialty of 
pharmaceutical medicine and a professional membership 
organisation for pharmaceutical physicians and those 
with a professional interest in the specialty. Founded 
in 1989, it is a faculty of the three Royal Colleges of 
Physicians of the United Kingdom: The Royal College of 
Physicians of London, The Royal College of Physicians 
of Edinburgh, and The Royal College of Physicians and 
Surgeons of Glasgow.
Although the Faculty has a strong affiliation with 
its parent colleges and shares their overall aims, the 
orga nisation is self-governed and independent. The 
Faculty is a registered charity and therefore exists for 
the benefit of patients and the public. It was founded 
with the mission: “To advance the science and practice 
of pharmaceutical medicine by working to develop 
and maintain competence, ethics and integrity and the 
highest professional standards in the specialty for the 
benefit of the public.”
2. History and Development
Medicines have a central role in clinical practice, and the 
need for the medical profession to be closely involved 
in their development and surveillance was recognised by 
the pharmaceutical industry in the mid-1950s, when a 
small but increasing number of doctors were employed 
as medical advisers. 
In 1963, in the wake of the thalidomide disaster, the 
setting up by the government of the Committee on 
Safety of Drugs (The Dunlop Committee) and the sub­
sequent formation of the Committee on Safety of Me­
dicines, one of the advisory committees established by 
The Medicines Act 1968, reinforced the need for spe­
cially trained doctors in the pharmaceutical industry, 
academic departments of medicine and the Department 
of Health and Social Security. In 1976, the Diploma in 
Pharmaceutical Medicine was established to be gained 
by examination.
The rapid evolution of the role of pharmaceutical 
physicians, and the developing interface between pharma-
ceutical medicine and other medical disciplines, led to 
the proposal to create a faculty of the Royal Colleges 
of Physicians, so that criteria could be esta blished lead-
ing to specialist certification of practi tioners, and with 
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it the public recognition of the ethical and professional 
practices which ensured that new medicines are de-
veloped, approved and monitored to the highest stand-
ards. The Faculty of Pharmaceutical Medicine was 
esta blished in 1989, and at the time of its inauguration 
comprised 400 members. Today, the Faculty has over 1,600 
members in over 40 countries. Members are pharma-
ceutical physicians who work to develop medicines and 
vaccines both in the UK and across the world. 
3. Pharmaceutical Medicine
The Faculty was established within a distinct medical 
scientific discipline, pharmaceutical medicine, which 
for over 40 years has advanced in the area of discovery, 
development, evaluation, registration, monitoring and 
medical aspects of marketing of medicines for the benefit 
of patients and the health of the public. Pharmaceutical 
medicine occupies common ground between the clinical 
and healthcare professions, pharmaceutical industry and 
government. Whilst the boundaries of pharmaceutical 
medicine are indistinct, at its centre is the clinical testing 
of medicines, translation of drugs into new medicines, the 
safety and well-being of research participants in clinical 
trials, and a pursuit of understanding of the safety of 
medicines and their benefit­risk balance. 
Pharmaceutical medicine is a discipline that takes its 
place alongside other medical specialties; it has developed 
its own professional ethos; it has established a distinct 
body of knowledge based primarily on clinical science; its 
practitioners represent a cohesive group of professionals 
and specialists with common goals and aspirations. 
Pharmaceutical physicians work with industry, medicines 
regulatory authorities, clinical research organisations 
and academic centres. They have close affinities with 
medical colleagues in primary and secondary health-
care and in universities. As a postgraduate medical 
discipline, pharmaceutical medicine has a recognised 
international syllabus, training courses and examinations 
with qualifications and certification, its own research 
methodologies, and embraces new technologies and re-
gulations in pursuit of proof of efficacy, safety, quality 
and effectiveness of medicines. 
Pharmaceutical medicine is a listed medical specialty 
in the UK, in Ireland, and in Switzerland, but around 
the world this remains a work in progress. This official 
re cognition is underlined by accredited education and 
training of pharmaceutical physicians in the specialty, 
and of the establishment and maintenance of standards 
of practice and professionalism in the competency, care 
and conduct applied to their work, and of growing public 
recognition and accountability. 
In April 2002, pharmaceutical medicine was offi-
cially recognised as a medical specialty in the United 
Kingdom. Trainees undertaking Pharmaceutical Medi-
cine Specialty Training (PMST) have a 4­year pro­
gramme of in-work competency-based training in early 
characterisation of potential medicines, clinical de-
velopment, safety and risk management and medical 
affairs within the healthcare marketplace, together with 
general interpersonal, management and leadership skills. 
On successful completion of PMST, trainees are entitled 
to apply to be on the UK GMC’s specialist register in 
pharmaceutical medicine. PMST is described in greater 
detail below.
4. A Functioning Faculty
Although the Faculty is based in the UK, it has an 
extensive international membership, with currently 
around 25% of its membership based outside the UK, in 
over 40 countries around the world.
The organisation is based in Islington, North London, 
and has an office staff of nine, who administer the 
training programmes and examinations, and support the 
Faculty’s Board and committees. 
The Faculty’s honorary officers are the President, Vice 
President, Registrar and Treasurer and other committee 
members are elected or appointed from the Faculty’s 
general membership. The Faculty Board, which includes 
the officers and other Faculty members, has legal 
responsibility for the operation of the Faculty as unpaid 
trustees of the charity.
Faculty members have opportunities to support the 
development of the specialty and the Faculty by becoming 
trained Faculty examiners, educational supervisors, 
specialty advisers and appraisers for medical revalidation.
Faculty activities include: membership engagement, 
examinations, medical revalidation, continuing profes-
sional development, the PMST programme, qualifications 
in human pharmacology and experimental therapeutics; 
committee and working party activities; advocacy 
work; international liaison and collaboration; scientific 
meetings and events, and publications.
In 2014, the Faculty celebrated the 25th anniversary of 
its foundation. During the course of the year a number 
of special events were organised and a webpage cata-
loguing the history and achievements of the Faculty was 
created[1]. 
5. Examinations and Training
The principal function of the Faculty is to set, maintain 
and raise standards in the specialty. Alongside PMST, 
the Faculty sets the syllabus for and administers the 
Diploma in Pharmaceutical Medicine, and training 
programmes and examinations in human pharmacology, 
outlined in Figure 1.
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6. Advocacy, PR and Careers
An important part of the Faculty’s work is in advocating 
for the highest standards of practice for the benefit 
of patients and the public health. The Faculty is in-
creasingly being recognised as an authoritative voice 
on pharmaceutical medical issues, both in the UK 
and around the world. Its views are now increasingly 
being sought by UK and international organisations, 
and the media, and it is represented on many external 
committees and groups, which enable its voice and that 
of its membership to be heard widely.
Through its network of committees and shared interest 
groups, the Faculty responds frequently to external 
consultations. These are mostly issued by the UK 
Government and UK and European regulatory agencies, 
but it also comments on policy documents from orga-
nisations such as the Prescription Medicines Code of 
Practice Authority, European Commission, World Health 
Organisation and World Medical Association. Links to 
some of the most recent consultations can be found on 
the Faculty website[2]. 
The Faculty undertakes a variety of activities to raise 
the profile of pharmaceutical medicine as a career option 
for doctors, such as attendance at careers fairs or invited 
lectures and presentations on pharmaceutical medicine. 
7. Ethics and Standards
In addition to the core work of training and exami-
nations, the Faculty also advocates and maintains 
rigo rously the highest standard of ethical practice 
amongst its membership and beyond. The Faculty 
first produced its ethical touchstone, the “Guiding 
Principles for Pharmaceutical Physicians” in 1998 and 
this was updated and formally published in 2006[3], 
with further revision in November 2010, as a result of a 
recommendation in the report by the Royal College of 
Physicians, “Innovating for health: Patients, physicians, 
the pharmaceutical industry and the NHS”.  
In 2014, the Good Pharmaceutical Medical Practice 
(GPMP) document was published[4]. GPMP provides all 
doctors practising pharmaceutical medicine around the 
world with specific guidance and direction on expected 
standards, conduct and behaviour. GPMP com plements 
international and national legislation and has been 
written to apply to all circumstances to ensure that it 
contains universal standards of good medical practice 
in pharmaceutical medicine. GPMP extends upon the 
principles outlined in its first publication in 2008 of 
GPMP, and the Guiding Principles for Pharmaceutical 
Physicians of 2010. GPMP encourages all pharma­
ceutical physicians to promote probity and adhere to 
the highest ethical principles and ideals, wherever they 
Figure 1. The examinations and training programmes of the Faculty
Diploma in Pharmaceutical Medicine
An examination for physicians working in pharmaceutical medicine covering all aspects of the specialty, as part 
of the PMST programme or as a standalone examination.
Diploma in Human Pharmacology
A 2-year programme and examination for physicians working in pharmaceutical medicine or allied 
field covering the knowledge and competencies required to serve as a principal investigator for human 
pharmacology studies of investigational medicinal products.
Certificate in Human Pharmacology
A 1-year part-time programme and examination for physicians, scientists and clinical research managers 
covering all aspects of human pharmacology studies of investigational medicinal products.
Diploma in Experimental Therapeutics
An 18-month supervised workplace-based training programme and examination, intended for physicians 
conducting Phase I/II studies predominantly in patients within their clinical specialty, e.g. oncology, 
rheumatology, in a hospital clinical research facility.
Pharmaceutical Medicine Specialty Training (PMST)
A 4-year supervised workplace-centred certification programme with knowledge assessed in the Diploma 
in Pharmaceutical Medicine examination, and the demonstration of competencies across 7 domains of the 
curriculum within a framework of assessment, appraisal and annual review of competence progression. On 
completion pharmaceutical physicians receive a Certificate of Completion of Training (CCT) and a place on the 
UK GMC’s specialist register in pharmaceutical medicine.
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practice, and act as an advocate for patients.
The Good Pharmaceutical Medical Practice Support 
Network[4] has also been established, to provide guidance 
and direction to pharmaceutical physicians who face 
ethical or medical dilemmas in their practice. The network 
is free to use and is available to all registered doc tors 
involved in the practice of pharmaceutical medicine, 
anywhere in the world. A panel of experienced Faculty 
Fellows has volunteered to give guidance to those 
who contact the network, whether they are a seasoned 
professional or a trainee. The scope of the network 
includes: enquiries directly related to the interpretation 
and adoption of the standards set out in GPMP; questions 
of research practice and ethics; and interpretation and 
implementation of global regulations, ethics and culture.
8. Medical Revalidation
Medical revalidation was introduced in the UK in 
December 2012. Revalidation is the process by which 
all licensed doctors are required to demonstrate on a 
regular basis that they are up to date and fit to practise. 
Revalidation aims to give extra confidence to patients 
that their doctor is being regularly checked by the 
UK GMC. Licensed doctors must revalidate every five 
years. During this time they maintain a portfolio of 
supporting information drawn from their practice, 
which demonstrates how they are continuing to meet 
the principles and values set out in Good Medical 
Practice (GMP)[5]. They also have regular appraisals. The 
Faculty has developed specialty specific standards for 
revalidation and is the designated body for almost 600 of 
its members.
9. Specialty Training in Pharmaceutical 
Medicine
The purpose of PMST is to equip doctors with specialist 
knowledge and comprehensive skills and competencies 
to practise to the highest ethical and professional 
standards in the discovery, development, evaluation, re-
gistration, regulation and the safe use of medicines. 
Whilst PMST is not a mandatory programme, most com­
panies and organisations employing pharmaceutical 
physicians in the UK support the programme and en-
courage participation. As of January 2017, over 310 
pharma ceutical physicians have completed PMST, to 
receive their Certificate of Completion of Training (CCT) 
from the UK GMC. There are over 140 enrolled trainees 
undertaking PMST at any one time, and each year some 
35 doctors join the programme, whilst around the same 
number complete training.  
All trainees follow the same overall curriculum and 
structure, though the balance of in-work to course-
based training will vary depending on the role the indi-
vidual is undertaking in their workplace. The PMST 
programme allows for considerable individual variation 
and flexibility in a trainee’s approach to meeting the 
requirements of the curriculum, and an overall individual 
programme takes account of the trainee’s experience, 
job description and content, and career development as-
pirations. The principal modules of the curriculum are: 
medicines regulation, clinical pharmacology, statistics 
and data management, clinical development, healthcare 
marketplace, drug safety surveillance and interpersonal, 
management and leadership skills.
The Faculty accepts applications for PMST from 
doctors from all medical specialties. The criteria that 
doctors must fulfil to enter are that they are registered 
with the UK GMC with a licence to practise, work for 
a UK-based pharmaceutical organisation that has been 
approved as a Local Education Provider (LEP) to deliver 
the PMST programme, and have completed approved 
clinical training and/or experience over a period of three 
or four years, depending on the year of their medical 
qualification.
10. Formation and Development of the 
Curriculum
In April 2002, the UK Parliament approved pharma-
ceutical medicine as a medical specialty in the UK. 
With the recognition of the specialty, the Faculty work-
ed to develop the specialty training programme to 
provide pharmaceutical physicians with broad train ing, 
completed in the workplace, in all fields of pharma-
ceutical medicine, which would lead to eligibility to 
apply for registration on the UK GMC’s specialist re gister 
in pharmaceutical medicine on successful completion of 
the programme. 
The project involved the development of a higher me-
dical training curriculum in pharmaceutical medicine, 
today known as PMST, which was achieved with the 
help of a Delphi exercise conducted by the University 
of Keele to identify the core topics for the curriculum. 
This higher medical training programme was approved 
by the Specialist Training Authority (STA) in 2002. The 
knowledge-based assessment of the curriculum was the 
Faculty’s existing Diploma in Pharmaceutical Medicine 
examination. Recent changes to the curriculum have seen 
the requirement for trainees to achieve attainment levels 
replaced by the requirement to demonstrate achieve ment 
of competencies through the assessment of the trainee’s 
applied knowledge, skills and behaviours.
Postgraduate medical education and specialty training 
in the United Kingdom continue to evolve, and it is 
the Faculty’s aim and responsibility to ensure that its 
PMST programme is up­to­date and relevant to current 
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practice and the needs of patients. The Faculty is currently 
under taking a review of the curriculum with the aim 
to introduce new Competencies in Practice (CiPs) for 
pharmaceutical medicine, which will lead ultimately to 
a very new-look curriculum for postgraduate training in 
the specialty. This is a development required by the Joint 
Royal Colleges of Physicians Training Board (JRCPTB) 
of all its specialties. The last almost 15 years of the 
Faculty’s specialty training programme have seen major 
changes to postgraduate medical education in the UK, 
and the Faculty aims that its PMST programme will meet 
those changes to ensure that specialist pharmaceutical 
physicians meet the needs of future patients.  More detail 
about PMST is available via the referenced link[6].
11. Oversight and Quality Management
The management of the PMST curriculum involves a 
wide range of organisations and people: the trainees 
themselves; the pharmaceutical companies, CROs and 
regulatory authorities which must be approved by the 
UK GMC as LEPs to deliver the PMST curriculum; 
the approved educational supervisors who supervise 
and assess their trainees; the medical postgraduate 
dean who is responsible for the management of the 
PMST programme and the trainees; the members of 
the Annual Review of Competence Progression panels 
who meet trainees to formally review their progress 
through the PMST programme; the Faculty’s team of 
Specialty Advisers who quality manage the delivery of 
the PMST programme by the LEPs, and the staff of the 
Pharmaceutical Medicine Virtual Deanery, together with 
the Lead Postgraduate Dean under whose auspices the 
PMST programme is delivered.
12. The Future
The Faculty continues to grow and mature as an orga-
nisation. It is growing in terms of numbers of its 
mem bers and trainees, and also in terms of the less 
tangible, but no less important, aspects of influence 
and impact on practice. The next few years will be 
an exciting time for the organisation as it embarks on 
an ambitious programme of policy development. It is 
hoped that the Faculty’s international reputation and 
recognition through its membership in many countries 
around the world will evolve into more tangible colla-
borations with organisations and representative bodies 
in the area of pharmaceutical medicine and medicines 
development science. The Faculty is currently launching 
two major new work streams; one looking at early 
access to medicines and adaptive licensing, and the 
other examining the potential value of different types 
of real world data in pharmaceutical medicine. Most 
important of all is that the Faculty continues to acquire 
the recognition, the strength and the strategic vision 
to promote actively at home and abroad its founding 
mission, “To advance the science and practice of 
pharmaceutical medicine by working to develop and 
maintain competence, ethics and integrity and the 
highest professional standards in the specialty for the 
benefit of the public.”
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